BNP Paribas Financial Markets Buys New Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)

BNP Paribas Financial Markets acquired a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 35,657 shares of the company's stock, valued at approximately $916,000.

Other hedge funds have also recently added to or reduced their stakes in the company. National Bank of Canada FI bought a new position in NewAmsterdam Pharma during the 4th quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. bought a new position in NewAmsterdam Pharma during the 4th quarter worth $80,000. KLP Kapitalforvaltning AS bought a new position in NewAmsterdam Pharma during the 4th quarter worth $154,000. Barclays PLC increased its stake in NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company's stock worth $126,000 after acquiring an additional 7,199 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new position in NewAmsterdam Pharma during the 4th quarter worth $221,000. Institutional investors own 89.89% of the company's stock.

Analyst Ratings Changes

NAMS has been the topic of a number of research analyst reports. Needham & Company LLC reduced their target price on NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a report on Monday, March 3rd. Scotiabank raised their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a report on Thursday, February 27th. Finally, Wall Street Zen downgraded NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.00.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ NAMS traded down $0.67 during mid-day trading on Friday, hitting $17.61. 274,673 shares of the stock traded hands, compared to its average volume of 637,089. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $27.29. The company has a market cap of $1.93 billion, a PE ratio of -9.37 and a beta of 0.01. The firm has a 50 day simple moving average of $18.58 and a two-hundred day simple moving average of $21.24.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The company had revenue of $2.98 million during the quarter, compared to the consensus estimate of $1.46 million. On average, equities research analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Activity at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 150,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,000 shares of the company's stock, valued at $305,550. This trade represents a 90.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James N. Topper bought 1,135 shares of the stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average cost of $22.49 per share, with a total value of $25,526.15. Following the completion of the transaction, the director now owns 3,013,569 shares in the company, valued at $67,775,166.81. The trade was a 0.04% increase in their ownership of the stock. The disclosure for this purchase can be found here. 20.84% of the stock is currently owned by company insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.